CD40LG and neoplasm: Another example, the AlloVax vaccine, is based on chaperone protein-enriched tumor cell lysate from the patient’s tumor (calreticulin, hsp70, hsp90, and gr94/gp96 as sources of tumor neoantigen) and the AlloStim adjuvant, which is composed of ex vivo differentiated Th1 memory T cells expressing CD40L and INF-γ.